Is Gilteritinib a targeted drug?

Gilteritinib (Gilteritinib) is a targeted drug. Its mechanism of action is to interfere with abnormal signaling pathways in leukemia cells by inhibiting the activity of FLT3 (FMS-like tyrosine kinase 3) receptor tyrosine kinase. FLT3 Receptor tyrosine kinase plays a role in regulating cell growth and differentiation in normal cells, but in FLT3 mutation-positive acute myeloid leukemia (AML) patients, the FLT3 gene is mutated, leading to abnormal activation of the FLT3 receptor, promoting abnormal proliferation and growth of leukemia cells.

Giritinib's targeting effect mainly targets FLT3 mutated leukemia cells, thereby helping to control the development of leukemia. Therefore, it is considered a targeted therapy that acts more specifically on leukemia cells without having a significant impact on normal cells. Compared with traditional chemotherapy methods, targeted therapy usually has lower toxic side effects.

Giritinib is currently on the market in China, but it is not included in medical insurance. If patients need it, they can go to the hospital to buy it at their own expense, but the price is very high, about about 35,000 yuan. For specific prices, please consult the local hospital pharmacy. Foreign original drugs of gilitinib are even more expensive. For example, the price of the Hong Kong version of the original drug is around 90,000 yuan, and the European version of the original drug is as high as more than 200,000 yuan, which is simply unaffordable for ordinary patients. But what is gratifying is that there are already foreign generic drugs of giritinib, mainly Laotian generic drugs. The price is about four to five thousand yuan, which is relatively cheap. In terms of drug ingredients, the ingredients of domestic and foreign original gilitinib drugs are basically the same as those of generic drugs.